Publicaciones en colaboración con investigadores/as de Dana–Farber Cancer Institute (144)

2024

  1. A road map for the treatment of pediatric diffuse midline glioma

    Cancer Cell

  2. AI is a viable alternative to high throughput screening: a 318-target study

    Scientific Reports, Vol. 14, Núm. 1

  3. Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors

    Journal for ImmunoTherapy of Cancer, Vol. 12, Núm. 3

  4. Joint EANM-SNMMI guideline on the role of 2-[18F]FDG PET/CT in no special type breast cancer: (endorsed by the ACR, ESSO, ESTRO, EUSOBI/ESR, and EUSOMA)

    European Journal of Nuclear Medicine and Molecular Imaging

  5. Joint EANM-SNMMI guidelines on the role of 2-[18F]FDG PET/CT in no special type breast cancer: differences and agreements with European and American guidelines

    European Journal of Nuclear Medicine and Molecular Imaging

  6. Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma

    Blood cancer discovery, Vol. 5, Núm. 3, pp. 146-152

2023

  1. Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways

    Cancer Discovery, Vol. 13, Núm. 11, pp. 2370-2393

  2. Consumption of olive oil and risk of breast cancer in U.S. women: results from the Nurses’ Health Studies

    British Journal of Cancer, Vol. 129, Núm. 3, pp. 416-425

  3. Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)

    Leukemia

  4. Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis from the Randomized Phase II ELOQUENT-3 Trial

    Journal of Clinical Oncology, Vol. 41, Núm. 3, pp. 568-578

  5. Leukemia-intrinsic determinants of CAR-T response revealed by iterative in vivo genome-wide CRISPR screening

    Nature Communications, Vol. 14, Núm. 1

  6. Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma

    The New England journal of medicine, Vol. 389, Núm. 11, pp. 1009-1022

  7. Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100

    Gynecologic Oncology, Vol. 178, pp. 119-129

  8. Overall Survival with Maintenance Olaparib at a 7-Year Follow-Up in Patients with Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial

    Journal of Clinical Oncology, Vol. 41, Núm. 3, pp. 609-617

  9. Overall Survival with Maintenance Olaparib at a 7-Year Follow-up in Patients with Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial

    Obstetrical and Gynecological Survey

  10. Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteria

    Seminars in Hematology

  11. Report of consensus panel 5 from the 11th international workshop on Waldenstrom's macroglobulinemia on COVID-19 prophylaxis and management

    Seminars in Hematology

  12. Safety and management of niraparib monotherapy in ovarian cancer clinical trials

    International Journal of Gynecological Cancer, Vol. 33, Núm. 6, pp. 971-981

  13. TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory

    Cancer Cell, Vol. 41, Núm. 11, pp. 1911-1926.e8

  14. Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023

    Annals of Oncology